SureTrader Advertisement Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator TREND1, conix, MadHatter326, KingDMC, Peter
Search This Board:
Last Post: 12/1/2015 8:09:56 PM - Followers: 321 - Board type: Free - Posts Today: 24


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Current Report Filing (8-k) 11/25/2015 05:12:39 PM
MNKD News: 3 Earnings Reports That Surprised Us This Quarter 11/21/2015 09:41:03 AM
MNKD News: MannKind Announces Senior Management Changes 11/20/2015 08:00:00 AM
MNKD News: MannKind Announces Senior Management Changes 11/20/2015 08:00:00 AM
MNKD News: MannKind's Desperation Move Comes Up Short -- Now What? 11/19/2015 04:22:02 PM
#15987  Sticky Note SHORT INTEREST: 10/30/2015 ---120,021,454 conix 11/11/15 10:08:03 PM
#13561  Sticky Note $MNKD MannKind Relies on 'Death Spiral' Fi Peter 07/29/15 06:48:01 PM
#8377  Sticky Note Not Looking Good For MNKD! MadHatter326 02/13/15 02:37:35 PM
#16258   January-November total of 91 doctors, the average monthly WHS 12/01/15 08:09:56 PM
#16257   Sanofi control the number of doctors. That is WHS 12/01/15 07:54:33 PM
#16256   QUOTE .......................................................... Mannkind Brea TREND1 12/01/15 04:27:35 PM
#16255   MNKD chart conix 12/01/15 04:10:50 PM
#16254   Mannkind Breakout Coming! jimmac 12/01/15 03:31:41 PM
#16253   Looks like MNKD may gap up tomorrow jimmac 12/01/15 03:29:43 PM
#16252   Rebalancing Buy? 2 M shares tonight? mr10001 12/01/15 01:06:21 PM
#16251   $5 is doable if initials of the new TREND1 12/01/15 12:33:24 PM
#16250   SNY is moving to 3 main product divisions jimmac 12/01/15 12:26:19 PM
#16249   QUOTE .................................................... new CEO PR will spi TREND1 12/01/15 12:12:32 PM
#16248   Afrezza in UK/ Europe can be announced at jimmac 12/01/15 12:06:34 PM
#16247   The new CEO can be announced at any time! jimmac 12/01/15 12:04:09 PM
#16246   The Afrezza story is just beginning. jimmac 12/01/15 12:02:41 PM
#16245   MNKD 10 MINUTES TREND1 12/01/15 11:23:07 AM
#16244   quote .......................................................... Why SNY will TREND1 12/01/15 11:17:59 AM
#16243   Half the states have no doctors on the list. TREND1 12/01/15 11:10:11 AM
#16242   QUOTE ....................................................... I'm here because the $2 support has TREND1 12/01/15 11:03:22 AM
#16241   Number of Doctors On This List: 91 WHS 12/01/15 09:13:10 AM
#16240   I'm here because the $2 support has held jimmac 12/01/15 09:06:02 AM
#16239   Why SNY will renew... Fear another competitor will jimmac 12/01/15 09:02:51 AM
#16237   That is normal in a down trend TREND1 12/01/15 12:06:22 AM
#16234   is that the UK/Europe trials pending approval. jimmac 11/30/15 09:19:18 PM
#16233   Yes....extremely over sold. martind18 11/30/15 08:59:47 PM
#16232   MNKD MONTHLY TREND1 11/30/15 08:14:39 PM
#16231   By the way what the hell happened to Hypi 11/30/15 06:25:05 PM
#16230   Well pretty crappy Thanksgiving and hopefully not the Hypi 11/30/15 05:56:53 PM
#16229   scripts part of discussion TREND1 11/30/15 03:06:25 PM
#16228   That is the kind of CEO we need. Jumpinjackas 11/30/15 02:51:13 PM
#16227   *****SCRIPTS 11/20/15 TREND1 11/30/15 01:26:44 PM
#16226   Pharma CEO: We’re in Business of Shareholder Profit, martind18 11/30/15 12:30:22 PM
#16225   Yes. As long as the new CEO gets Jumpinjackas 11/30/15 10:07:53 AM
#16224   new CEO PR will spike MNKD to $5+ jimmac 11/30/15 09:44:56 AM
#16223   Hakan will be working with the company up Saborte79 11/30/15 09:02:05 AM
#16222   QUOTE ....................................................... look for a partner in Europe TREND1 11/28/15 03:00:06 PM
#16221   quote --------------------------------------------------------- Will be glad w TREND1 11/27/15 11:13:44 AM
#16220   Will be glad when the fun and games kugel 11/27/15 11:10:24 AM
#16219   MNKD UPDATE TREND1 11/27/15 10:52:58 AM
#16218   MNKD 10 MINUTES TREND1 11/27/15 10:50:52 AM
#16217   adding mnkd, 2016 should see a modest increase harry crumb 11/27/15 10:15:07 AM
#16216   ***** MNKD WEEKLY TREND1 11/26/15 10:22:28 PM
#16214   Very well said martind18 eom. redfalcon2 11/26/15 02:47:01 AM
#16213 martind18 11/25/15 05:15:20 PM
#16212   Should I jump in or wait till we Gregwit 11/25/15 02:02:05 PM
#16211   Sure it is. Any month now TREND1 11/25/15 12:15:12 PM
#16210   This is going worldwide and its just a Hypi 11/25/15 12:06:56 PM
#16209   No, the opposite with only few trading days Jumpinjackas 11/25/15 11:09:05 AM
#16208   By looking at the monthly, weekly or daily COO2002COO 11/25/15 11:06:40 AM
#16207   COO When you want to buy MNKD long TREND1 11/25/15 10:56:59 AM
#16205   Yes, we need a ceo with experience in Jumpinjackas 11/25/15 08:44:39 AM
#16204   A PR of a new CEO appointment is COO2002COO 11/25/15 08:32:55 AM